Antibody indexes in COVID-19 convalescent plasma donors: Unanswered questions

Bonetti, Tatiana Carvalho de Souza; Latini, Flavia Roche Moreira; Invitti, Adriana Lukow; Fonseca, Marcelo Cunio Machado; Scorza, Fulvio Alexandre; Saldanha, Maira Garcia; Bellucco, Fernanda T.; Bacarov, Natalia B.S.; Soane, Michel M.; Girão, Manoel João Batista Castelo.
Clinics ; 76: e2818, 2021. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1339704

Documentos relacionados

  1. Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection.
  2. Human Antibodies for Viral Infections.
  3. ABO blood group does not influence the level of anti-SARS-CoV-2 antibodies in convalescent plasma donors.
  4. Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell-depleting agents.
  5. Factors related to the development of high antibody titres against SARS-CoV-2 in convalescent plasma donors from the ConPlas-19 trial.
  6. Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients.
  7. A possible dose-response equation: Viral load after plasma infusion in COVID-19 patients and anti-SARS-CoV-2 antibody titers in convalescent plasma.
  8. [Treatment of SARS-CoV-2 in paediatrics : what is the evidence to date?]
  9. Reduced neutralizing antibody potency of COVID-19 convalescent vaccinated plasma against SARS-CoV-2 Omicron variant.
  10. High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies.